obsolete_common variable immunodeficiency: ['A hypogammaglobulinemia that is results in insufficient production of antibodies needed to respond to exposure of pathogens and is characterized by low Ig levels with phenotypically normal B cells that can proliferate but do not develop into Ig-producing cells. Patients with common variable immunodeficiency have marked reduction in serum levels of both immunoglobulin G (IgG) and immunoglobulin A (IgA); about half of these patients also have reduced immunoglobulin M (IgM).', 'A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.', 'Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpoints |
253 |
6. Filter based on genotype QC (FinnGen only) |
226 |
Control definitions (FinnGen only)
- Control exclude
- D3_IMMUNEMECHANISM
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D80-D89
- Name in latin
- Deficientia immunalis variabilis communis
Similar endpoints
↥List of similar endpoints to
Common variable immunodeficiency
based on the number of shared cases.
Similar with more cases:
- Immunodeficiencies
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
- Other or unspecified common variable immunodeficiency
- Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
- Common variable immunodeficiency with predominant abnormalities of T-cell numbers and function
- Common variable immunodeficiency with autoantibodies to B- or T-cells
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 938 | 523 | 407 |
| Only index persons | 837 | 484 | 353 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 50.88 | 51.24 | 50.30 |
| Only index persons | 49.07 | 50.37 | 47.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 226 | 139 | 87 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | 48.91 | 50.27 | 46.73 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 231
- Matched controls
- 2310
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
131.1
113
*
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
124.6
108
*
D83.9
ICD-10 Finland
Common variable immunodeficiency, unspecified
+∞
113.1
99
*
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
105.5
93
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
103.0
91
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
27.3
99.6
75
40
J47
ICD-10 Finland
Bronchiectasis
44.2
79.6
49
14
ZX120
NOMESCO Finland
Intravenous
11.1
64.0
85
115
D83.1
ICD-10 Finland
Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
+∞
50.9
47
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
18.1
48.9
42
28
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
48.7
45
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.8
46.4
83
155
J01MA14
ATC
moxifloxacin; systemic
8.7
46.1
71
112
6BA02, ,
NOMESCO Finland
535.8
45.9
44
*
TDM10
NOMESCO Finland
Puncture of maxillary antrum
12.5
45.9
50
50
UGC12
NOMESCO Finland
Flexible bronchoscopy
11.0
45.5
55
64
D83.8
ICD-10 Finland
Other common variable immunodeficiencies
+∞
44.2
41
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
11.8
41.8
47
49
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
8.2
41.6
66
107
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
+∞
39.7
37
*
J01MA12
ATC
levofloxacin; systemic
6.1
38.3
94
235
D80.0
ICD-10 Finland
Hereditary hypogammaglobulinaemia
+∞
36.4
34
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
8.0
34.6
54
85
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.2
33.3
106
326
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.8
32.8
52
83
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
8.7
32.6
46
64
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
7.6
31.6
51
83
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.8
31.4
116
399
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.0
29.9
160
721
TPH04
NOMESCO Finland
Cathetrisation of vein
4.6
28.1
97
312
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
27.7
26
*
H02AB06
ATC
prednisolone; systemic
4.7
27.0
163
783
GD1AD
NOMESCO Finland
Thorax CT examination
7.7
27.0
42
65
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.1
26.6
54
110
C01CA24
ATC
epinephrine; parenteral
6.6
26.3
48
88
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
8.4
24.9
35
48
R50.9
ICD-10 Finland
Fever, unspecified
4.7
24.6
73
206
Z01.8
ICD-10 Finland
Other specified special examinations
4.3
24.5
89
293
WW200
NOMESCO Finland
Immunization
21.5
23.9
35
19
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
8.4
23.5
33
45
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
23.8
23.3
33
16
H02AB07
ATC
prednisone; oral
4.6
21.3
62
171
J01FA15
ATC
telithromycin; oral
5.1
21.0
51
121
J01FA06
ATC
roxithromycin; oral
3.5
19.7
135
660
M05BA04
ATC
alendronic acid; oral
5.4
19.4
43
94
UDH02
NOMESCO Finland
Rhinopharyngoscopy
5.4
19.1
42
91
J45.9
ICD-10 Finland
Asthma, unspecified
3.7
18.2
75
263
J01.0
ICD-10 Finland
Acute maxillary sinusitis
3.4
18.2
107
471
D86.0
ICD-10 Finland
Sarcoidosis of lung
+∞
17.9
17
*
UJF30
NOMESCO Finland
Ileoscopy through colon
4.4
17.2
50
136
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.2
17.0
31
56
OAB50, ,
SPAT
5.3
16.8
37
80
Z3231
NOMESCO Finland
Registered nurse
3.3
16.7
95
406
J01MA02
ATC
ciprofloxacin; systemic
3.2
16.7
115
550
J45.1
ICD-10 Finland
Nonallergic asthma
5.0
16.1
38
87
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
+∞
15.8
15
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.9
15.7
38
89
XW000
NOMESCO Finland
Bone marrow biopsy
7.3
15.6
24
36
Z2221
NOMESCO Finland
Medical doctor
3.1
15.0
95
427
SPAT1262
SPAT
Handing over of treatment supplies
3.6
15.0
60
204
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.4
14.9
42
111
R03BB04
ATC
tiotropium bromide; inhalant
4.9
14.9
36
84
A07EA06
ATC
budesonide; oral, local oral
6.4
14.8
26
45
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
6.4
14.8
26
45
WE300
NOMESCO Finland
Profylactive therapy of malignancy with biomoidiers
+∞
14.7
14
*
D86.9
ICD-10 Finland
Sarcoidosis, unspecified
+∞
14.7
14
*
J01FF01
ATC
clindamycin; systemic
3.0
14.7
95
431
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
14.3
106
518
TGC00
NOMESCO Finland
Bronchial lavation
12.6
14.2
25
22
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
32.3
14.1
18
6
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.2
14.0
73
292
A07AA02
ATC
nystatin; oral
5.6
13.8
28
56
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
6.6
13.7
23
38
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.3
13.5
39
105
R03DA04
ATC
theophylline; systemic, rectal
6.4
13.3
23
39
H02AB04
ATC
methylprednisolone; systemic
3.4
13.1
56
198
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
3.1
13.0
68
271
J45.0
ICD-10 Finland
Predominantly allergic asthma
4.0
12.8
41
119
UJF32
NOMESCO Finland
Coloscopy
2.9
12.8
80
353
J32.4
ICD-10 Finland
Chronic pansinusitis
14.3
12.7
21
16
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
6.7
12.7
21
34
M36.8*D80.1
ICD-10 Finland
Systemic disorders of connective tissue in hypogammaglobulinaemia
+∞
12.6
12
*
UJF92
NOMESCO Finland
Capsular endoscopy
11.5
12.6
23
22
H02AB09
ATC
hydrocortisone; systemic
13.5
12.4
21
17
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
28.5
12.2
16
6
J45.8
ICD-10 Finland
Mixed asthma
9.4
11.9
24
28
Z3226
NOMESCO Finland
Physiotherapist
3.0
11.6
64
261
132
Kela drug reimbursment
Sarcoidosis
+∞
11.6
11
*
D86.2
ICD-10 Finland
Sarcoidosis of lung with sarcoidosis of lymph nodes
+∞
11.6
11
*
D80.2
ICD-10 Finland
Selective deficiency of immunoglobulin A [IgA]
+∞
11.6
11
*
WX892
NOMESCO Finland
Monitored bed care
4.8
11.3
27
62
R01AD09
ATC
mometasone; nasal
2.6
11.2
138
841
R03AK06
ATC
salmeterol and fluticasone; inhalant
3.2
11.2
52
192
XF400
NOMESCO Finland
ECG with 12 standard connections
3.3
11.1
49
175
R01AD05
ATC
budesonide; nasal
4.2
11.0
32
86
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.1
10.9
53
201
J05AB11
ATC
valaciclovir; oral
3.0
10.9
59
238
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
29.6
10.9
14
5
WW500
NOMESCO Finland
Blood transfusion
5.7
10.8
21
40
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
9.9
10.8
21
23
B99
ICPC
Blood/lymph/spleen disease other
63.0
10.7
12
*
A02BC01
ATC
omeprazole; systemic
2.7
10.6
80
384
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
9.5
10.5
21
24
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
5.3
10.5
22
45
J06BA02
ATC
immunoglobulins, normal human, for intravascular adm.; systemic
+∞
10.5
10
*
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.6
10.5
154
1008
R03BA02
ATC
budesonide; inhalant
2.8
10.4
66
289
SPAT1255
SPAT
Intravenous administration of medicine
4.5
10.2
26
63
WZC00
NOMESCO Finland
Treatment plan or consultation
2.5
10.1
109
616
S01AA01
ATC
chloramphenicol; ophthalmic
4.9
10.0
23
51
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.7
9.9
65
290
J46
ICD-10 Finland
Status asthmaticus
9.8
9.7
19
21
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
9.5
51
203
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
104.1
9.5
10
*
J02AC01
ATC
fluconazole; systemic
2.4
9.4
113
665
D07BA04
ATC
hydrocortisone and antiseptics; topical
3.6
9.2
33
103
J01DA08
ATC
[U] cefaclor
3.1
9.0
42
154
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.2
9.0
19
39
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
25.2
9.0
12
5
A07AA09
ATC
vancomycin; oral
25.2
9.0
12
5
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.4
8.9
87
465
C03CA01
ATC
furosemide; systemic
2.5
8.8
71
348
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
52.0
8.7
10
*
A10AB05
ATC
insulin aspart; parenteral
3.6
8.7
31
96
Z31.5
ICD-10 Finland
Genetic counselling
3.8
8.7
28
81
J01FA09
ATC
clarithromycin; systemic
2.3
8.7
93
517
J01AA02
ATC
doxycycline; systemic
2.9
8.6
193
1472
R03AC02
ATC
salbutamol; inhalant
2.3
8.5
149
1013
D70.89
ICD-10 Finland
Neutropenic splenomegaly
13.5
8.5
14
11
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.8
8.4
47
191
D83.2
ICD-10 Finland
Common variable immunodeficiency with autoantibodies to B- or T-cells
+∞
8.4
8
*
D73.1
ICD-10 Finland
Hypersplenism
+∞
8.4
8
*
J01FA10
ATC
azithromycin; systemic
2.4
8.4
161
1137
ZXD05
NOMESCO Finland
Urgent procedure
2.3
8.2
84
455
XQ800
NOMESCO Finland
Prick test
3.7
8.2
28
84
J01DA06
ATC
[U] cefuroxime
2.7
8.1
51
220
B29
ICPC
Lymph/immune mech sympt/complt other
23.0
8.1
11
5
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
8.1
74
382
JN4BD
NOMESCO Finland
Extensive body CT
3.3
8.0
33
112
R03DC03
ATC
montelukast; oral
2.7
8.0
52
228
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.4
8.0
30
96
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
13.7
8.0
13
10
R03AC12
ATC
salmeterol; inhalant
4.3
7.8
21
53
GD1CG
NOMESCO Finland
Extensive examination of lungs and pleura with high intensity magnet
46.6
7.8
9
*
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
2.2
7.7
145
998
R03AK07
ATC
formoterol and budesonide; inhalant
2.4
7.7
63
308
ZXD10
NOMESCO Finland
Scheduled procedure
2.2
7.7
100
595
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.0
7.7
38
144
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
9.3
7.7
15
17
129
Kela drug reimbursment
Idiopathic thrombocytopaenia or granulocytopenia
26.0
7.6
10
*
C10AC01
ATC
colestyramine; oral
6.9
7.6
18
28
J01DA01
ATC
[U] cefalexin
2.2
7.5
156
1113
R4110
NOMESCO Finland
Physiotherapy
2.3
7.5
78
424
WVC10
NOMESCO Finland
Subcutaneous infusion of drugs
14.0
7.5
12
9
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.5
7.4
53
243
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.4
7.4
19
46
JN3AD
NOMESCO Finland
Abdominal CT examination
2.8
7.4
40
159
ZXA05
NOMESCO Finland
Left side
2.4
7.4
66
335
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.7
7.4
46
197
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
11.4
7.4
13
12
P01AB01
ATC
metronidazole; oral, rectal
2.1
7.3
107
664
K90.8
ICD-10 Finland
Other intestinal malabsorption
+∞
7.3
7
*
D84.9
ICD-10 Finland
Immunodeficiency, unspecified
+∞
7.3
7
*
D84.8
ICD-10 Finland
Other specified immunodeficiencies
+∞
7.3
7
*
XG410
NOMESCO Finland
Flow-volume spirometry
6.4
7.2
18
30
ZXA00
NOMESCO Finland
Right side
2.3
7.2
70
368
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.2
7.2
31
108
1XC02, ,
NOMESCO Finland
31.1
7.2
9
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
20.8
7.2
10
5
ZXE10
NOMESCO Finland
More than one and less than three hours
2.1
7.2
95
567
J31.0
ICD-10 Finland
Chronic rhinitis
2.9
7.1
35
132
R05
ICD-10 Finland
Cough
2.4
7.1
61
304
N02AX02
ATC
tramadol; systemic, rectal
2.1
7.1
111
706
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.2
7.0
19
48
R03AC13
ATC
formoterol; inhalant
4.0
7.0
20
53
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
2.2
6.9
85
491
WZC30
NOMESCO Finland
Teaching
2.5
6.9
51
237
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
6.0
6.9
18
32
ZXE20
NOMESCO Finland
More than three and less than five hours
2.6
6.9
43
184
ZXE00
NOMESCO Finland
One hour or less
2.1
6.9
101
624
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
17.3
6.8
10
6
E83.1
ICD-10 Finland
Disorders of iron metabolism
41.3
6.8
8
*
JA2AT
NOMESCO Finland
Abdominal puncture with ultrasound guidance
41.3
6.8
8
*
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
5.8
6.8
18
33
R03AK08
ATC
formoterol and beclometasone; inhalant
4.3
6.8
18
45
A40.3
ICD-10 Finland
Sepsis due to Streptococcus pneumoniae
23.3
6.7
9
*
JN4AD
NOMESCO Finland
Body CT examination
2.9
6.7
34
131
J01DC02
ATC
cefuroxime; systemic
3.8
6.6
21
60
ZXA10
NOMESCO Finland
Bilateral
2.4
6.6
53
256
GD1DG
NOMESCO Finland
Extremely extensive MRI examination of pleura with high field magnet
71.8
6.5
7
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.4
6.3
14
20
R03BA01
ATC
beclometasone; inhalant
2.6
6.3
39
166
D80.6
ICD-10 Finland
Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinaemia
+∞
6.3
6
*
D89.89
ICD-10 Finland
Other specified disorders involving the immune mechanism, not elsewhere classified
+∞
6.3
6
*
D81.0
ICD-10 Finland
Severe combined immunodeficiency [SCID] with reticular dysgenesis
+∞
6.3
6
*
K52.88
ICD-10 Finland
Other specified noninfective gastroenteritis and colitis
6.1
6.3
16
28
ZX121
NOMESCO Finland
Central venous catheter
27.5
6.3
8
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
2.7
6.2
36
149
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
5.8
6.1
16
29
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.2
6.0
60
317
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
80
13
93.61
149.54
2.3
1.5
—
—
—
0
0
138
137
23.54
137.10
5.8
1.8
0.82
1.46
g/l
1.53
112
131
64
19
46.21
103.90
2.5
1.2
458.84
802.85
e6/l
0.88
51
13
64
21
41.77
100.91
2.7
1.3
185.22
194.63
e6/l
0.08
51
16
76
8
140.32
74.30
6.6
1.3
815.38
1250.75
u/ml
—
76
8
61
5
164.70
60.20
3.1
1.2
16.16
12.80
u/l
—
61
5
42
20
25.44
57.18
2.1
1.4
0.55
0.62
e9/l
0.25
42
20
78
145
7.61
43.54
2.2
1.2
93.49
333.44
u/ml
0.77
46
134
147
502
6.30
42.87
5.7
1.4
1.23
2.30
g/l
11.19
90
313
48
61
9.67
36.80
1.8
1.2
—
—
—
0
0
46
57
9.83
35.92
3.0
3.0
—
—
—
0
0
39
40
11.53
34.86
6.8
5.9
231.67
178.00
iu/ml
—
6
5
65
141
6.02
30.25
2.9
1.6
—
—
—
0
0
77
220
4.75
25.67
2.7
1.7
—
—
—
0
0
37
53
8.12
25.40
2.2
1.6
—
—
—
0
0
47
88
6.45
25.20
2.9
1.5
—
—
—
0
0
90
294
4.38
25.15
3.3
1.9
—
—
—
0
0
37
54
7.97
24.98
2.3
1.8
—
—
—
0
0
34
45
8.69
24.90
1.7
1.5
—
—
—
0
0
199
1176
6.00
23.61
28.8
10.0
3.51
3.95
e9/l
2.57
189
1028
29
36
9.07
22.27
1.6
1.5
—
—
—
0
0
21
0
+∞
22.24
2.1
0.0
0.43
—
mg/l
—
13
0
21
0
+∞
22.24
2.1
0.0
0.53
—
mg/l
—
12
0
21
0
+∞
22.24
2.1
0.0
1.31
—
mg/l
—
13
0
21
0
+∞
22.24
2.1
0.0
1.41
—
mg/l
—
10
0
21
0
+∞
22.24
2.1
0.0
0.40
—
mg/l
—
13
0
21
0
+∞
22.24
2.1
0.0
2.56
—
mg/l
—
13
0
21
0
+∞
22.24
2.1
0.0
0.64
—
mg/l
—
9
0
21
0
+∞
22.24
2.1
0.0
2.99
—
mg/l
—
11
0
21
0
+∞
22.24
2.1
0.0
0.57
—
mg/l
—
11
0
21
0
+∞
22.24
2.1
0.0
1.18
—
mg/l
—
14
0
29
41
7.95
19.99
1.5
1.3
—
—
—
0
0
67
206
4.17
19.80
2.9
1.8
—
—
—
0
0
23
5
50.82
19.59
1.8
1.8
1.49
1.40
ratio
—
23
5
81
289
3.78
19.32
3.1
2.6
143.07
111.35
ug/g
0.44
70
232
36
71
5.82
18.08
1.6
2.3
1.39
1.42
g/l
0.04
30
63
109
488
3.34
17.97
4.5
2.1
2.86
3.06
mg/l
0.43
102
432
24
33
8.00
16.86
2.4
2.1
—
—
—
0
0
24
35
7.54
16.02
1.6
1.6
—
—
—
0
0
19
5
41.13
15.64
1.2
1.0
82.32
102.60
%
—
19
5
161
962
3.22
15.32
11.8
7.4
1.21
1.22
mmol/l
0.68
151
824
25
20
13.86
14.78
1.2
1.5
—
—
—
0
0
26
24
12.05
14.43
1.6
1.3
—
—
—
0
0
150
904
2.88
13.26
5.3
2.6
77.09
76.26
nmol/l
0.15
143
820
23
41
6.12
12.69
1.5
1.4
—
—
—
0
0
103
525
2.74
12.43
4.9
3.2
0.40
0.40
e6/l
0.01
85
381
24
28
9.43
11.86
1.5
1.7
—
—
—
0
0
20
18
12.04
11.29
4.0
2.5
—
—
—
0
0
21
21
10.88
11.27
1.9
1.7
—
—
—
0
0
20
19
11.41
11.01
3.0
1.0
—
—
—
0
0
20
19
11.41
11.01
3.0
1.0
—
—
—
0
0
20
19
11.41
11.01
4.1
2.4
—
—
—
0
0
25
56
4.88
10.77
2.9
3.1
7.80
1.22
index
—
10
32
26
62
4.60
10.40
1.4
1.2
399.45
336.28
ug/g
0.92
20
30
34
101
3.77
10.18
1.3
2.3
4.68
5.23
iu/ml
—
9
27
29
77
4.16
10.13
2.3
1.3
—
—
—
0
0
19
37
5.51
9.53
1.4
1.5
—
—
—
0
0
26
68
4.18
9.24
3.3
1.3
—
—
—
0
0
21
48
4.71
8.81
2.0
2.0
—
—
—
0
0
163
1145
2.44
8.76
7.2
5.0
6.72
6.56
mmol/l
0.36
158
1078
17
19
9.56
8.70
4.6
3.5
—
—
—
0
0
47
191
2.83
8.41
7.2
10.9
-0.17
1.04
mmol/l
0.89
35
160
31
100
3.43
8.18
2.4
1.7
—
—
—
0
0
23
61
4.08
8.02
1.2
1.3
—
—
—
0
0
126
814
2.21
7.98
2.7
2.1
87.58
98.81
pmol/l
1.68
78
403
12
9
13.98
7.47
1.2
1.0
—
—
—
0
0
94
555
2.17
7.32
2.3
1.7
18.82
21.53
nmol/l
1.33
89
474
15
19
8.36
7.23
2.6
1.3
1.06
0.07
u/ml
—
10
9
150
1071
2.14
6.98
5.4
3.6
0.00
0.00
estimate
-0.00
37
229
150
1082
2.10
6.65
5.5
3.6
34.89
0.00
estimate
0.49
38
233
133
925
2.03
6.43
3.3
2.7
—
—
estimate
—
0
0
16
27
6.28
6.43
2.1
1.6
—
—
—
0
0
16
27
6.28
6.43
4.5
1.5
—
—
—
0
0
16
27
6.28
6.43
4.5
1.5
—
—
—
0
0
150
1090
2.07
6.42
5.3
3.7
0.08
0.00
estimate
0.49
37
217
49
232
2.41
6.36
9.6
7.1
104.33
104.22
mmol/l
0.05
49
232
16
28
6.06
6.27
4.6
1.5
—
—
—
0
0
16
28
6.06
6.27
4.6
1.5
—
—
—
0
0
16
28
6.06
6.27
4.5
1.5
—
—
—
0
0
16
28
6.06
6.27
4.5
1.5
—
—
—
0
0
13
17
8.03
6.21
1.2
1.8
—
—
—
0
0
21
63
3.57
6.16
1.5
1.4
0.02
0.01
iu/ml
—
6
9
13
18
7.58
6.01
2.8
1.8
—
—
—
0
0
13
18
7.58
6.01
2.8
1.8
—
—
—
0
0
13
18
7.58
6.01
2.8
1.8
—
—
—
0
0
54
275
2.26
5.91
1.9
1.7
1391.90
1162.92
nmol/l
0.72
48
214
21
66
3.40
5.75
4.3
2.0
—
—
—
0
0
21
68
3.30
5.50
3.6
2.2
—
—
—
0
0
11
15
7.64
5.20
1.4
1.1
—
—
—
0
0
14
27
5.45
5.17
2.1
1.3
—
—
—
0
0
47
239
2.21
5.12
3.1
2.5
10.82
6.70
umol/l
0.51
42
213
15
32
4.94
5.09
1.6
1.5
—
—
—
0
0
15
32
4.94
5.09
1.6
1.5
—
—
—
0
0
8
7
11.78
4.82
1.5
1.0
—
—
—
0
0
8
7
11.78
4.82
1.5
1.0
—
—
—
0
0
54
300
2.04
4.67
3.5
3.3
1.64
2.92
e6/l
0.99
27
141
7
5
14.37
4.60
1.4
3.2
—
—
iu/ml
—
0
0
8
8
10.30
4.55
5.2
5.9
—
—
—
0
0
8
8
10.30
4.55
3.5
1.1
98.55
62.38
ug/l
—
8
8
100
689
1.80
4.46
3.5
3.3
2.30
2.36
mmol/l
5.29
94
627
75
473
1.87
4.46
3.6
2.2
—
—
—
0
0
9
12
7.75
4.39
2.3
1.3
131.00
109.42
pmol/l
—
9
12
18
61
3.12
4.39
1.7
1.2
—
—
—
0
0
18
61
3.12
4.39
1.7
1.2
—
—
—
0
0
8
9
9.16
4.31
2.0
1.1
160.75
53.01
u/l
—
8
9
8
9
9.16
4.31
2.0
1.1
54.00
15.86
u/l
—
8
9
84
555
1.81
4.27
1.4
1.3
2.09
1.48
u/ml
0.14
16
143
23
93
2.64
4.11
5.7
3.7
1.85
1.89
mmol/l
0.01
15
68
55
321
1.94
4.10
3.3
3.1
1.28
0.73
e6/l
0.51
28
163
86
584
1.75
3.93
5.9
3.7
0.00
0.01
estimate
0.74
34
216
6
5
12.27
3.78
2.3
1.4
0.60
0.63
mmol/l
—
6
5
24
104
2.46
3.74
4.4
4.1
24.74
24.39
mmol/l
0.23
24
104
8
12
6.86
3.70
2.8
1.8
—
—
—
0
0
8
12
6.86
3.70
2.8
1.8
—
—
—
0
0
8
12
6.86
3.70
2.8
1.8
—
—
—
0
0
8
12
6.86
3.70
2.8
1.8
—
—
—
0
0
8
12
6.86
3.70
1.8
1.2
—
—
—
0
0
210
1866
2.38
3.68
35.1
13.5
86.83
85.61
ml/min/173m2
0.33
202
1724
166
1366
1.76
3.66
3.9
3.3
—
—
—
0
0
76
509
1.73
3.60
3.3
2.7
1377.89
1126.28
ng/l
0.15
67
416
6
6
10.22
3.51
1.2
1.0
—
—
—
0
0
71
472
1.73
3.43
2.0
1.8
1.02
1.17
mg/l
0.25
56
368
7
10
7.18
3.39
1.9
2.6
—
—
—
0
0
7
10
7.18
3.39
1.9
2.6
—
—
—
0
0
11
29
3.93
3.23
1.5
1.2
—
—
—
0
0
8
15
5.48
3.22
1.8
1.7
—
—
—
0
0
7
11
6.52
3.21
1.3
1.1
—
—
—
0
0
217
1979
2.59
3.17
48.0
14.1
17.09
21.31
mg/l
2.15
206
1582
95
696
1.62
3.12
4.3
3.2
27.01
35.24
ng/l
0.38
66
437
6
8
7.66
3.07
1.7
2.1
—
—
—
0
0
28
142
2.11
3.06
4.7
3.5
1.22
1.22
mmol/l
0.05
28
118
194
1707
1.85
3.00
48.8
17.6
14.10
13.49
%
7.25
194
1696
5
5
10.18
2.99
1.0
1.2
—
—
—
0
0
5
5
10.18
2.99
1.0
1.4
—
—
—
0
0
5
5
10.18
2.99
1.0
1.0
—
—
—
0
0
5
5
10.18
2.99
1.0
1.2
—
—
—
0
0
5
5
10.18
2.99
1.0
1.0
—
—
—
0
0
13
46
2.93
2.97
1.3
1.4
—
—
—
0
0
20
90
2.34
2.89
3.2
2.5
0.61
0.61
%
0.02
20
90
6
9
6.81
2.88
1.7
2.1
—
—
—
0
0
6
9
6.81
2.88
3.0
2.0
—
—
—
0
0
6
9
6.81
2.88
2.2
1.6
—
—
—
0
0
6
9
6.81
2.88
1.2
1.3
103.17
1000.89
mg
—
6
9
6
9
6.81
2.88
3.0
2.0
—
—
—
0
0
6
9
6.81
2.88
2.2
1.6
—
—
—
0
0
6
9
6.81
2.88
1.7
2.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
10
6.12
2.71
1.0
1.2
—
—
—
0
0
6
10
6.12
2.71
3.0
1.9
—
—
—
0
0
56
370
1.68
2.71
2.4
2.7
2.41
2.44
mmol/l
1.58
49
321
20
93
2.26
2.70
3.2
2.5
2.17
1.32
%
0.92
20
93
29
157
1.97
2.67
2.1
1.4
—
—
—
0
0
26
137
2.01
2.58
2.4
2.6
72.46
69.75
ml/min/173m2
0.09
13
59
5
7
7.27
2.56
1.0
1.7
—
—
—
0
0
5
7
7.27
2.56
1.0
1.1
—
—
—
0
0
6
11
5.57
2.56
2.2
1.5
—
—
—
0
0
6
11
5.57
2.56
2.2
1.5
—
—
—
0
0
105
816
1.53
2.54
5.6
3.4
0.00
0.02
estimate
0.68
34
196
22
111
2.09
2.45
1.5
1.2
—
—
—
0
0
6
12
5.10
2.41
2.2
2.5
0.50
0.83
index
—
6
12
81
602
1.53
2.38
4.6
4.2
6.15
10.47
mg/mmol
0.89
54
365
9
28
3.30
2.33
1.2
1.1
—
—
—
0
0
14
60
2.42
2.26
1.6
3.2
33.30
54.42
mg/l
—
9
53
9
29
3.19
2.25
1.2
1.1
—
—
—
0
0
11
43
2.63
2.11
1.2
1.2
—
—
—
0
0
5
10
5.08
2.08
1.2
1.0
—
—
—
0
0
7
20
3.58
2.07
1.3
1.3
—
—
—
0
0
6
15
4.08
2.05
3.0
2.6
—
—
—
0
0
65
476
1.51
2.01
4.8
3.5
1.02
1.02
kg/l
0.04
50
322
16
78
2.13
1.96
1.5
1.3
—
—
—
0
0
8
27
3.03
1.95
1.4
1.2
—
—
—
0
0
8
28
2.92
1.88
1.3
1.4
0.19
0.18
nmol/l
—
8
20
6
17
3.59
1.85
1.2
1.2
—
—
—
0
0
29
178
1.72
1.84
3.9
3.0
—
—
—
0
0
5
12
4.23
1.83
2.6
1.9
80.40
109.58
%
—
5
12
7
23
3.11
1.81
2.9
4.3
3.64
2.56
nmol/l
—
7
23
11
47
2.41
1.80
1.2
1.3
—
—
—
0
0
179
1937
0.66
1.76
4.5
4.8
1.37
1.48
mmol/l
2.50
172
1810
26
157
1.74
1.75
1.7
1.2
20.69
144.23
u/ml
—
10
61
15
75
2.07
1.74
3.8
3.2
12.53
2308.15
u/ml
0.67
15
65
22
128
1.79
1.67
2.5
3.0
4.54
4.65
pmol/l
0.29
22
110
7
25
2.85
1.66
1.3
1.1
—
—
—
0
0
183
1967
0.66
1.65
5.3
5.6
2.55
2.77
mmol/l
2.60
176
1842
54
400
1.46
1.56
1.5
1.3
23.72
10.84
u/ml
0.37
22
158
51
377
1.45
1.49
5.0
3.3
19.24
134.12
ng/l
2.52
32
264
5
16
3.17
1.44
2.4
1.8
—
—
—
0
0
77
624
1.35
1.31
4.9
3.0
0.00
0.01
estimate
0.50
35
186
6
24
2.54
1.31
1.8
1.7
—
—
—
0
0
5
18
2.82
1.29
1.8
1.2
—
—
—
0
0
5
18
2.82
1.29
1.4
1.2
—
—
—
0
0
5
18
2.82
1.29
1.4
1.2
—
—
—
0
0
5
18
2.82
1.29
1.0
1.1
—
—
—
0
0
15
250
0.57
1.28
1.5
2.0
3.71
3.49
ratio
—
9
200
8
36
2.27
1.25
1.1
1.1
—
—
—
0
0
5
19
2.67
1.22
1.4
1.2
—
—
—
0
0
5
19
2.67
1.22
1.4
1.2
—
—
—
0
0
6
26
2.34
1.19
1.3
1.2
—
—
—
0
0
171
1834
0.74
1.16
4.0
4.1
1.38
1.25
mmol/l
1.43
163
1703
11
58
1.94
1.14
1.1
1.1
—
6.43
—
0
7
5
21
2.41
1.09
1.4
1.2
—
—
—
0
0
54
426
1.35
1.09
1.5
1.4
18.48
38.48
iu/ml
1.62
12
131
171
1581
1.31
1.03
5.0
4.5
15.03
14.66
pmol/l
1.15
161
1461
5
23
2.20
0.98
1.0
1.0
—
—
—
0
0
22
151
1.51
0.94
2.2
2.6
—
21.39
—
0
10
20
136
1.52
0.90
1.3
1.4
—
34.78
—
0
10
76
881
0.80
0.87
2.0
2.0
1.39
1.36
mmol/l
0.13
70
750
0
24
0.00
0.79
0.0
1.6
—
—
—
0
0
194
1846
1.32
0.79
6.3
5.4
1.95
1.83
mu/l
0.81
186
1719
11
67
1.67
0.76
1.6
1.7
—
—
—
0
0
26
194
1.38
0.75
14.3
6.1
—
—
—
0
0
7
39
1.82
0.73
2.7
2.1
8.57
7.21
pmol/l
—
7
39
5
27
1.87
0.69
1.0
1.0
—
—
—
0
0
17
120
1.45
0.66
3.2
1.5
0.24
0.28
mg/l
—
8
55
9
59
1.55
0.55
1.2
1.2
—
—
—
0
0
11
75
1.49
0.51
1.6
1.6
7.14
10.05
u/ml
—
5
13
20
154
1.33
0.50
2.6
2.1
—
—
—
0
0
7
47
1.50
0.48
1.7
1.3
—
—
—
0
0
6
91
0.65
0.43
1.0
1.1
1.32
1.52
g/l
—
6
91
6
93
0.64
0.43
1.0
1.1
1.03
0.91
g/l
—
6
93
5
32
1.57
0.42
1.4
1.2
4.66
8.22
mmol/l
—
5
24
188
1818
1.18
0.41
6.9
5.9
38.92
38.51
mmol/mol
0.20
182
1722
0
19
0.00
0.39
0.0
1.4
—
197.93
—
0
19
53
472
1.16
0.38
1.5
1.6
—
—
—
0
0
22
181
1.24
0.36
2.9
2.1
—
—
—
0
0
7
91
0.76
0.23
1.3
1.6
195.14
281.99
mu/l
—
7
83
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
39
361
1.10
0.16
1.5
1.5
—
—
—
0
0
7
86
0.81
0.15
1.6
1.6
—
—
—
0
0
32
299
1.08
0.11
2.8
2.9
0.60
0.73
ug/l
0.75
23
164
5
47
1.07
0.09
1.8
2.0
0.92
0.95
nmol/l
—
5
39
5
63
0.79
0.08
2.4
1.6
—
—
—
0
0
31
326
0.94
0.07
2.8
2.2
—
—
—
0
0
15
162
0.92
0.06
2.1
2.7
0.10
0.15
e6/l
0.42
15
152
29
303
0.95
0.05
2.9
2.1
—
—
—
0
0
39
383
1.02
0.01
3.3
4.1
20.98
22.76
%
0.32
20
150
12
117
1.03
0.00
1.1
1.0
—
—
—
0
0
188
1883
0.99
0.00
5.5
4.7
5.92
5.84
mmol/l
0.27
179
1751
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
8.35
—
0
9
0
9
0.00
0.00
0.0
1.2
—
9.61
—
0
9
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
7
70
1.00
-0.00
1.6
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
66.78
—
0
6
5
52
0.96
-0.00
2.4
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
1.18
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
34.22
—
0
5
0
5
0.00
-0.00
0.0
3.0
—
37.20
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_CVID and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_CVID | 3.228 [2.32, 4.48] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.337 |
During the follow-up period (1.1.1998 — 31.12.2019), 106 out of 476 females with D3_CVID died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_CVID | 3.026 [2.02, 4.54] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 104 out of 347 males with D3_CVID died.
Mortality risk
Mortality risk for people of age
years, who have D3_CVID.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.287% | 0.681% |
| 5 | 2.034% | 3.255% |
| 10 | 5.02% | 7.718% |
| 15 | 8.881% | 14.648% |
| 20 | 15.33% | 23.297% |
Relationships between endpoints
↥Index endpoint: D3_CVID – Common variable immunodeficiency
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data